ADAR1 Capital Management »

Y Mabs Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Y Mabs Therapeutics (YMAB) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Y Mabs Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Y Mabs Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Y Mabs Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $89k 13k 6.82

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Y Mabs Therapeutics

BlackRock
Vanguard Group
D. E. Shaw & Co
Caligan Partners
Acadian Asset Management
Dimensional Fund Advisors
Goldman Sachs Group
Jacobs Levy Equity Management
Charles Schwab Investment Management
Connor, Clark & Lunn Investment Management
Two Sigma Advisers
Soleus Capital Management
Citadel Advisors
Thomas Stevens, CFA"
Marshall Wace

View all funds holding Y Mabs Therapeutics